Trends in the Engineering of Adeno-Associated Virus (AAV) for Precision Gene Delivery to the Central Nervous System (CNS).

Sola Oloruntimehin, Alexander Malogolovkin

Abstract readReview

In one paragraph

Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Sola OloruntimehinLaboratory of Molecular Virology, E.I. Martsinovsky Institute of Medical Parasitology, Tropical and Vector-Borne Diseases, Clinical Center, I.M. Sechenov First Moscow State Medical University, Moscow 119991, Russia.ORCID 0000-0003-4078-7007

Alexander MalogolovkinLaboratory of Molecular Virology, E.I. Martsinovsky Institute of Medical Parasitology, Tropical and Vector-Borne Diseases, Clinical Center, I.M. Sechenov First Moscow State Medical University, Moscow 119991, Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rare genetic disorders of the central nervous system (CNS) remain some of the most complex and challenging diseases to treat for several reasons. Targeting the CNS, especially the brain, presents one of the greatest obstacles in gene therapy using adeno-associated virus (AAV) vectors. Although various AAVs have been identified for their ability to transduce different cells in the CNS, their effectiveness and efficiency are significantly limited by the presence of neutralising antibodies (NAbs) and restricted cargo capacity. Despite these challenges, our understanding of AAV structure and technological advances continue to enable researchers to develop innovative strategies that have resulted in groundbreaking, FDA-approved therapeutic products now available for Leber congenital amaurosis (LCA) (Luxturna

Indexed as

Central Nervous SystemCentral Nervous System DiseasesDependovirusGenetic TherapyGenetic VectorsGene Transfer TechniquesAnimalsGene Therapy AgentsHumansMuscular Atrophy, SpinalAADCDAAVAlzheimer’s diseasecentral nervous systemCNSneurodegenerativeParkinson’s diseasespinal muscular atrophy

Identifiers

PMID42449943

DOI10.3390/ijms27135668

PMCPMC13362290

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.